A chronological record of peer-reviewed PT-141 research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly PT-141works" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Melanocortin MC4R Agonism. Primary indications investigated: Female sexual desire, Erectile dysfunction (off-label research).
Network meta-analysis comparing efficacy and safety profiles of FDA-approved HSDD treatments using published trial data.
Safety analysis from Phase 3 trials examining cardiovascular effects in women with and without hypertension history.
Open-label extension of Phase 3 trials assessing long-term safety, efficacy, and tolerability of continuing bremelanotide beyond 12 weeks.
Phase 3 double-blind RCT evaluating bremelanotide 1.75mg subcutaneous injection in premenopausal women with acquired HSDD. Primary endpoint was change in desire domain score.
Second pivotal Phase 3 trial confirming bremelanotide efficacy in premenopausal women with generalized HSDD across 12 weeks of treatment.
Analysis of hyperpigmentation in bremelanotide trials, examining risk factors based on baseline skin tone and MC1R polymorphisms.
Exploratory analysis of Phase 3 trial data examining bremelanotide efficacy specifically in postmenopausal women with acquired HSDD.
Pivotal Phase 3 RECONNECT trials (combined n=1,247) meeting co-primary endpoints: significant increase in desire and reduction in distress vs placebo in premenopausal women with HSDD.
Clinical review summarizing the full bremelanotide development program including mechanism, Phase 2 and 3 results, safety profile, and practical prescribing considerations.
Study examining nausea mechanisms with bremelanotide and testing preventive strategies including antiemetic pretreatment and food administration.
Functional neuroimaging study measuring brain activation and genital blood flow response to bremelanotide versus placebo during erotic stimuli.
Cellular study examining melanogenesis induction by MC4R and MC1R agonism using cultured melanocytes and melanoma cells.
Study correlating bremelanotide plasma levels and MC4R occupancy (measured by PET imaging) with sexual arousal response.
Mechanistic study in rodents demonstrating MC4R coupling to dopamine signaling in nucleus accumbens during sexual approach behavior.
Phase 2 dose-finding RCT establishing 1.75mg as optimal dose. Bremelanotide significantly increased desire and reduced distress in premenopausal women with HSDD.
Phase 2b dose-finding study establishing optimal bremelanotide dose of 1.75mg for female HSDD. Tested doses of 0.5mg, 1.0mg, and 1.75mg.
Electrophysiologic study demonstrating MC4R-mediated modulation of oxytocin neurons in paraventricular nucleus and downstream sexual behavior effects.
Mechanistic study in rats demonstrating MC4R activation in medial preoptic area drives sexual motivation and erectile function through dopaminergic pathways.
Comprehensive review of melanocortin-mediated sexual function, comparing melanotan II, PT-141, and other MC4R agonists with emphasis on mechanism and safety.
Pharmacokinetic study establishing bremelanotide time-to-peak (60 min), half-life (26-42 min), and relationship between plasma levels and sexual response.
Comparative review of melanotan II and bremelanotide mechanisms, selectivity for melanocortin receptor subtypes, and differential safety profiles.
Review tracing the discovery pathway from melanotan II tanning trials through the serendipitous observation of sexual effects to focused PT-141 development for both male and female sexual dysfunction.
Pilot study of intranasal PT-141 in men with ED, including sildenafil-refractory patients. Measured penile rigidity and tumescence.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for PT-141 is L5 (FDA Approved): fda-approved for at least one human indication. Treat each study as one data point, not a conclusion.
PeptideMark indexes 56 studies on PT-141: 18 human studies, 25 animal studies, 5 in-vitro, and 8 reviews. The current evidence level is L5 — fda approved.
The earliest indexed peer-reviewed study on PT-141 in the PeptideMark library was published in 2004 (Journal of Urology). Research activity has continued through 2022.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Yes. Recent publications on PT-141 appear as recently as 2022, indicating ongoing investigation. See the research log on this page for the specific study.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.